Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT 3 COMBINATION PACK PREFILLED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTERICIN B versus MONISTAT 3 COMBINATION PACK PREFILLED.
AMPHOTERICIN B vs MONISTAT 3 COMBINATION PACK (PREFILLED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability and cause leakage of intracellular contents, leading to cell death.
Miconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
0.5-1.5 mg/kg/day IV over 2-6 hours; for invasive aspergillosis, 1 mg/kg/day; for cryptococcal meningitis, 0.7 mg/kg/day IV in combination with flucytosine; liposomal formulation: 3-5 mg/kg/day IV. Maximum dose: 1.5 mg/kg/day for conventional amphotericin B deoxycholate.
Intravaginal administration of one applicator (200 mg miconazole nitrate) at bedtime for 3 consecutive days.
None Documented
None Documented
Clinical Note
moderateAmphotericin B + Digoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digoxin."
Clinical Note
moderateAmphotericin B + Digitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin."
Clinical Note
moderateAmphotericin B + Deslanoside
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Deslanoside."
Clinical Note
moderateTerminal half-life: 24–48 hours initially, prolonged to 15 days with repeated dosing due to tissue redistribution.
Terminal elimination half-life is approximately 20-30 hours for miconazole after systemic absorption, reflecting slow elimination from deep tissue compartments.
Renal: ~2-5% unchanged; biliary/fecal: ~40% as metabolites; extensive tissue binding delays excretion.
Approximately 50% of absorbed dose excreted in feces via biliary elimination; <1% excreted unchanged in urine. Unabsorbed drug from vaginal administration is eliminated in vaginal discharge.
Category C
Category C
Antifungal
Antifungal
Amphotericin B + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Amphotericin B is combined with Acetyldigitoxin."